Results 31 to 40 of about 193,970 (395)

A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]

open access: yes, 2016
Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis   +10 more
core   +1 more source

Gut Microbiota in Diagnosis, Therapy and Prognosis of Cholangiocarcinoma and Gallbladder Carcinoma—A Scoping Review

open access: yesMicroorganisms, 2023
Cancers of the biliary tract are more common in Asia than in Europe, but are highly lethal due to delayed diagnosis and aggressive tumor biology. Since the biliary tract is in direct contact with the gut via the enterohepatic circulation, this suggests a
Ann-Kathrin Lederer   +8 more
doaj   +1 more source

The microbiota of the bilio-pancreatic system: A cohort, STROBE-compliant study [PDF]

open access: yes, 2019
Background: The gut microbiota play an essential role in protecting the host against pathogenic microorganisms by modulating immunity and regulating metabolic processes.
Agrusa A.   +8 more
core   +1 more source

Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas [PDF]

open access: yes, 2019
The bile duct system and pancreas show many similarities due to their anatomical proximity and common embryological origin. Consequently, preneoplastic and neoplastic lesions of the bile duct and pancreas share analogies in terms of molecular ...
Alvaro, D   +10 more
core   +1 more source

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.

open access: yesJAMA Oncology, 2020
Importance Currently, there is no established second-line systemic treatment for biliary tract cancer (BTC). Preclinical data have demonstrated that the presence of tumor-infiltrating CD8 T cells and programmed cell death 1 ligand 1-expressing tumor ...
R. Kim   +10 more
semanticscholar   +1 more source

Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.

open access: yesFuture Oncology, 2022
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of a humanized monoclonal anti-HER2 antibody, a cleavable tetrapeptide-based linker and a potent topoisomerase I inhibitor.
A. Ohba   +19 more
semanticscholar   +1 more source

Liver: Intrahepatic cholangiocarcinoma [PDF]

open access: yes, 2009
Review on Liver: Intrahepatic cholangiocarcinoma, with data on clinics, and the genes ...
Aishima, S, Enjoji, M
core   +1 more source

Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholagnitis [PDF]

open access: yes, 2018
The non-invasive differentiation of malignant and benign biliary disease is a clinical challenge. Carbohydrate antigen 19-9 (CA19-9), leucine-rich α2-glycoprotein (LRG1), interleukin 6 (IL6), pyruvate kinase M2 (PKM2), cytokeratin 19 fragment (CYFRA21.1)
Blyuss, O   +9 more
core   +2 more sources

Epidemiologic patterns of biliary tract cancer in the United States: 2001–2015

open access: yesBMC Cancer, 2022
Biliary tract cancer (BTC) includes intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma, gallbladder cancer, and ampulla of Vater cancer (AVC). Although BTC is rare in the US, incidence is increasing and elevated in certain populations.
J. Koshiol   +4 more
semanticscholar   +1 more source

16S rDNA microbiome composition pattern analysis as a diagnostic biomarker for biliary tract cancer

open access: yesWorld Journal of Surgical Oncology, 2020
Background The aim of this study is to investigate the composition of microbiota in biliary tract cancer patients and healthy adults by metagenome analysis and evaluate its potential values as biomarkers for biliary tract cancer.
Huisong Lee   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy